Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Inflammatory Waldenström macroglobulinemia is associated with monocyte dysregulation and IL-1β production

Blood (2025) 146 (Supplement 1): 1777.

https://doi.org/10.1182/blood-2025-1777

Published: 2025

Journal Articles

The molecular landscape of Waldenström macroglobulinemia identified using whole genome sequencing

Blood (2025) 146 (Supplement 1): 1770.

https://doi.org/10.1182/blood-2025-1770

Published: 2025

Journal Articles

Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.

Blood (2025) 146 (Supplement 1): 684.

https://doi.org/10.1182/blood-2025-684

Published: 2025

Journal Articles

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

Blood (2025) 146 (Supplement 1): 3883.

https://doi.org/10.1182/blood-2025-3883

Published: 2025

Journal Articles

A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes

Blood (2025) 146 (10): 1225–1238.

https://doi.org/10.1182/blood.2024028164

Published: 2025

Includes: Supplemental data

Journal Articles

Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

Blood (2025) 145 (4): 450–454.

https://doi.org/10.1182/blood.2024025738

Published: 2025

Includes: Supplemental data

Journal Articles

Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort

Blood (2024) 144 (Supplement 1): 4343.

https://doi.org/10.1182/blood-2024-193883

Published: 2024

Journal Articles

A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation

Blood (2024) 144 (Supplement 1): 857.

https://doi.org/10.1182/blood-2024-210654

Published: 2024

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Blood (2024) 144 (Supplement 1): 584.

https://doi.org/10.1182/blood-2024-194593

Published: 2024

Journal Articles

TRAF3 -Inactivated Chronic Lymphocytic Leukemia Cells Show an Enhanced Metabolic Plasticity That Can be Attenuated By Glutaminolysis and Mitochondrial Pyruvate Import Inhibition

Claudia Perez Carretero, Miguel Quijada Álamo, Mariana Tannoury, Léa Dehgane, Alberto Rodríguez-Sánchez, Teresa González, Maria Rocio Benito Sanchez, Elise Chapiro, Ana E. Rodriguez, Florence Nguyen-Khac, Santos A. Susin, Jesús María Hernández-Rivas

Blood (2023) 142 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2023-187054

Published: 2023

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

Andrea Visentin, Enrico Gaffo, Moritz Furstenau, Jennifer A. Woyach, Panagiotis Baliakas, Kerry A Rogers, Cecelia Miller, Claudia Haferlach, Karla Plevova, David Graham Oscier, Zadie Davis, Florence Nguyen Khac, Eleonora Roncaglia, Gian Matteo Rigolin, Anastasia Athanasiadou, Fanny Baran-Marszak, Alberto Valiente, Maria Jose Terol, Pau Abrisqueta, Blanca Espinet, Anna Puiggros, Annalisa Martines, Laura Bonaldi, Francesca Romana Mauro, Lydia Scarfo, Thomas Chatzikonstantinou, Eugen Tausch, Karl Anton Kreuzer, Arnon P. Kater, Francesc Bosch, Michael Doubek, Panayiotis Panayiotidis, Olga Kalashnikova, Federica Frezzato, Monica Facco, Valeria Ruocco, Alessia Buratin, Silvia Orsi, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavarretta, Ivan Zatta, Andrea Serafin, Robin Foa, Barbara F. Eichhorst, Antonio Cuneo, Kostas Stamatopoulos, Paolo Ghia, Stefania Bortoluzzi, Livio Trentin

Blood (2023) 142 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2023-174569

Published: 2023

Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Blood (2022) 140 (Supplement 1): 7013–7015.

https://doi.org/10.1182/blood-2022-157963

Published: 2022

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia

Claudia Pérez Carretero, Miguel Quijada Álamo, Mariana Tannoury, Léa Dehgane, David J. Sanz, Teresa González, Rocio Benito, Elise Chapiro, Maria Hernandez-Sanchez, Ana E. Rodriguez, Florence Nguyen Khac, Santos A. Susin, Jesús María Hernández-Rivas

Blood (2022) 140 (Supplement 1): 4105–4106.

https://doi.org/10.1182/blood-2022-168861

Published: 2022

Journal Articles

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, Manja Meggendorfer, Ferran Nadeu, Christian Brieghel, Helen Parker, Stamatia Laidou, Riccardo Moia, Davide Rossi, Mark Catherwood, Jana Kotaskova, Julio Delgado, Ana E Rodríguez-Vicente, Rocio Benito, Gian Matteo Rigolin, Silvia Bonfiglio, Lydia Scarfo, Mattias Mattsson, Zadie Davis, Ajay Gogia, Lata Rani, Panagiotis Baliakas, Cecilia Jylhä, Aron Skaftason, Inmaculada Rapado, Fatima Miras, Joaquin Martinez-Lopez, Javier de la Serna, Jesús M Hernández Rivas, Patrick Thornton, Maria Jose Larrayoz, María José Calasanz, Zoltán Mátrai, Csaba Bodor, Karin E. Smedby, Blanca Espinet, Anna Puiggros, Ritu Gupta, Lars Bullinger, Francesc Bosch, Bárbara Tazón, Fanny Baran-Marszak, David Oscier, Florence Nguyen-Khac, Thorsten Zenz, María José Terol, Antonio Cuneo, María Hernández-Sánchez, Sarka Pospisilova, Ken I Mills, Gianluca Gaidano, Carsten Utoft Niemann, Elías Campo, Jonathan C Strefford, Paolo Ghia, Kostas Stamatopoulos, Richard Rosenquist

Blood (2021) 138 (Supplement 1): 2617.

https://doi.org/10.1182/blood-2021-150648

Published: 2021

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blood (2021) 138 (Supplement 1): 641.

https://doi.org/10.1182/blood-2021-145624

Published: 2021

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

High frequency of clonal hematopoiesis in Erdheim-Chester disease

Fleur Cohen Aubart, Damien Roos-Weil, Marine Armand, Alice Marceau-Renaut, Jean-François Emile, Nicolas Duployez, Frédéric Charlotte, Stéphanie Poulain, Raphael Lhote, Zofia Hélias-Rodzewicz, Véronique Della-Valle, Olivier Bernard, Karim Maloum, Florence Nguyen-Khac, Jean Donadieu, Zahir Amoura, Omar Abdel-Wahab, Julien Haroche

Blood (2021) 137 (4): 485–492.

https://doi.org/10.1182/blood.2020005101

Published: 2021

Includes: Supplemental data

Journal Articles

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139210

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Inflammatory Waldenström macroglobulinemia is associated with monocyte dysregulation and IL-1β production

The molecular landscape of Waldenström macroglobulinemia identified using whole genome sequencing

Time-limited acalabrutinib monotherapy in frail patients with previously untreated chronic lymphocytic leukemia: Primary endpoint analysis of the randomized STAIR trial.

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes

Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort

A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

TRAF3 -Inactivated Chronic Lymphocytic Leukemia Cells Show an Enhanced Metabolic Plasticity That Can be Attenuated By Glutaminolysis and Mitochondrial Pyruvate Import Inhibition

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

High frequency of clonal hematopoiesis in Erdheim-Chester disease

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only